Literature DB >> 3145204

The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects.

C T Eason1, J I Usansky, G P Henry, P Powles, F W Bonner.   

Abstract

The pharmacokinetic characteristics of amrinone have been studied in six female marmosets following oral administration of 1, 12.5, 25, 50 and 75 mg.kg-1 and an intravenous dose of 1mg.kg-1. The mean plasma AUC0 infinity was determined at each dose level; the values obtained were 2.5, 18.7, 33.9, 103 and 312 micrograms.h.ml-1 for the oral doses of 1, 12.5, 25, 50 and 75 mg.kg-1 respectively and 1.9 micrograms.h.ml-1 for the intravenous dose of 1mg.kg-1. Mean maximum observed plasma concentrations were 0.6, 7.1, 11.7, 23.7 and 40.0 micrograms.ml-1 respectively following oral doses. Over the range 1 to 50 mg.kg-1 the AUC0 infinity was linear; at 75 mg.kg-1 the AUC0 infinity was disproportionately greater. Elimination appeared to be first order over the dose range 1 to 50 mg.kg-1 and the t1/2 in the marmoset was approximately 1 to 3 hours over this dose range. The plasma levels achieved are discussed in relation to the observed effects on the platelet population in this species following chronic administration at high dose levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145204     DOI: 10.1007/BF03191314

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  15 in total

1.  Platelet population profiles: significance of species variation and drug-induced changes.

Authors:  C T Eason; A Pattison; D D Howells; J Mitcheson; F W Bonner
Journal:  J Appl Toxicol       Date:  1986-12       Impact factor: 3.446

2.  The effects of amrinone, cyclophosphamide and anti-platelet serum on platelet production in the Gunn rat.

Authors:  C T Eason; A Pattison; D D Howells; F W Bonner; J F Martin
Journal:  J Appl Toxicol       Date:  1988-02       Impact factor: 3.446

Review 3.  Pharmacokinetics and toxicity testing.

Authors:  B Clark; D A Smith
Journal:  Crit Rev Toxicol       Date:  1984       Impact factor: 5.635

4.  Oral bioavailability and intravenous pharmacokinetics of amrinone in humans.

Authors:  G B Park; R P Kershner; J Angellotti; R L Williams; L Z Benet; J Edelson
Journal:  J Pharm Sci       Date:  1983-07       Impact factor: 3.534

5.  High-performance liquid chromatographic analysis of amrinone and its N-acetyl derivative in plasma. Pharmacokinetics of amrinone in the dog.

Authors:  M P Kullberg; B Dorrbecker; J Lennon; E Rowe; J Edelson
Journal:  J Chromatogr       Date:  1980-01-04

6.  Clinical safety of intravenous amrinone--a review.

Authors:  G Treadway
Journal:  Am J Cardiol       Date:  1985-07-22       Impact factor: 2.778

7.  The mechanism of hepatotoxicity of a chromone carboxylic acid (FPL 52757) in the dog.

Authors:  C T Eason; D V Parke; B Clark; D A Smith
Journal:  Xenobiotica       Date:  1982-03       Impact factor: 1.908

8.  Amrinone-mediated thrombocytopenia.

Authors:  E L Kinney; J O Ballard; B Carlin; R Zelis
Journal:  Scand J Haematol       Date:  1983-10

9.  Effect of oral amrinone on platelet function and survival.

Authors:  J T Brandt; L Miller; J Hermiller; D V Unverferth; C V Leier
Journal:  Clin Pharmacol Ther       Date:  1984-08       Impact factor: 6.875

10.  The pharmacokinetics of amrinone at three dose levels in the rabbit.

Authors:  G E Larijani; M L Rocci; D L Newman; H Wilson
Journal:  Pharm Res       Date:  1985-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.